Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Dry Eye Disease Market

Dry Eye Disease Market Share

Report ID: GMI4299
Published Date: Jul 2023
Report Format: PDF

Download Free Sample

Dry Eye Disease Market Share

Some of the major players operating in the dry eye disease market are:

AbbVie, Inc
AFT Pharmaceuticals
Alcon
Bausch & Lomb
Johnson & Johnson Services, Inc
Novartis AG
OASIS Medical
Otsuka Pharmaceutical Co., Ltd
Oyster Point Pharma Inc
Santen Pharmaceutical Co., Ltd
Sentiss Pharma Pvt. Ltd
Sun Pharmaceutical Industries Ltd
Thea Pharmaceuticals Ltd
VISUfarma
Takeda Pharmaceutical Company Ltd

These leading market players are implementing advanced technologies to cater to the large unmet needs of the consumers. These players focus on strategic partnerships, new product launch & commercialization for market expansion. Furthermore, these players are heavily investing in research that allows them to introduce innovative products and garner maximum revenue in the market.

Authors: Mariam Faizullabhoy , Shishanka Wangnoo

Frequently Asked Questions (FAQ) :

The global market for dry eye disease was valued at over USD 6 billion in 2022 and is projected to reach around USD 12.3 billion by 2032, owing to increasing prevalence of dry eye disease and associated ailments.

The cyclosporine segment accounted for over 35% market share in 2022. Cyclosporine is an immunomodulatory medication that has been found to provide several benefits in the diagnosis and treatment of dry eye disease.

North America dry eye disease market was valued at USD 2.4 billion in 2022 and will continue upward growth trend through 2032, ascribed to an increase in the number of patients suffering from dry eye disease, and expanding elderly population in the region.

AbbVie, Inc., AFT Pharmaceuticals, Alcon, Bausch & Lomb, Johnson & Johnson Services, Inc., Novartis AG, OASIS Medical, Otsuka Pharmaceutical Co., Ltd., Oyster Point Pharma, Inc., and Santen Pharmaceutical Co., Ltd. among others.